ABSTRACT Venlafaxine, a serotonin and norepinephrine reuptake inhibitor, is increasingly used in pregnant women with pre-existing depression who require continued treatment. However, its in utero effects on the developing fetus are not clear. Herein, we report the unusual presentation of venlafaxine withdrawal in a female preterm baby of 29 weeks gestation, who presented with myoclonic seizures on her second day of life. The seizures were confirmed using amplitude-integrated electroencephalography, and other possible causes of neonatal seizures were excluded. The baby responded to treatment with phenobarbitone and phenytoin. Magnetic resonance imaging of her brain was unremarkable at corrected gestational age of 39 weeks and 2 days. On follow-up at the corrected age of five months, she was well and developing normally with no further seizures. To the best of our knowledge, this is the first report of seizures in a preterm baby resulting from maternal venlafaxine use.
I NTRO D U C TIO N
Depression during pregnancy is common and can result in serious consequences for the mother, the newborn and their family. Adequate treatment of depression during pregnancy is of great importance for maternal, fetal and neonatal health.
(1) Venlafaxine, a serotonin and norepinephrine reuptake inhibitor, and selective serotonin reuptake inhibitors (SSRIs) are commonly used antidepressants in the general population; (2) these drugs are not uncommonly continued into the antepartum period when women with pre-existing depressive illness conceive. However, as most of these drugs cross the placenta in an erratic manner, their fetal effects are of concern. (3) Prolonged fetal exposure to venlafaxine and SSRIs may be associated with neonatal abstinence syndrome (NAS), which affects 30% of newborns. (4, 5) Not many studies have explored the effect of venlafaxine on preterm neonates, such as the type of seizure activity produced and the electrophysiological correlation. Herein, we present what we believe is the first reported case of myoclonic seizures in a preterm neonate, in whom epileptiform activity was documented using amplitude-integrated electroencephalography (aEEG).
The present case demonstrates that in utero exposure to venlafaxine can produce multifocal myoclonic seizures in babies born at 29 weeks of gestation.
CA S E R EPO RT
A 29-week-old preterm, large-for-gestational-age (birth weight Magnetic resonance imaging of her brain at the corrected gestational age of 39 weeks and 2 days was unremarkable. A review conducted at the corrected age of five months found that the baby's development was satisfactory, with an unremarkable neurological examination.
D I SCU S S IO N
The clinical presentation of drug withdrawal in neonates due to in utero venlafaxine exposure is varied. Premature birth may decrease the extent of the symptoms as there is a decrease in the duration of drug exposure prior to delivery. (6) While there are other reports of neonatal problems secondary to maternal venlafaxine, (7) (8) (9) only a few focused on seizure activity. We found reports of three cases of neonatal seizures as a result of in utero venlafaxine exposure; however, all three were observed in term neonates. (10, 11) To the best of our knowledge, the present case report is the first report of seizures in a preterm baby due to maternal venlafaxine use.
In the three previously reported cases of neonatal seizures, (10, 11) The diagnoses of neonatal seizures were made clinically in all of the previously reported cases except one; in that one case, the evidence of underlying seizure activity was recorded using conventional EEG. (11) The present case is the first reported case of epileptic activity in a baby with neonatal drug withdrawal due to in utero venlafaxine exposure, documented using aEEG. Normative values for aEEG background activity at different gestational ages have previously been published. (14, 15) The practical advantage of aEEG over conventional EEG in sick full-term and premature infants is that aEEG can be is very useful in assisting accurate interpretation of the patterns observed. (16) In the present case, concurrent EEG recording on CFM showed sharp spike wave tracings that corresponded to the high voltage tracings of the aEEG (Fig. 1) .
The use of antidepressant medication during pregnancy is unlikely to decrease in the near future. Therefore, consideration should be given to tapering the dose of all antidepressants, including venlafaxine, in the third trimester to decrease the risk of withdrawal symptoms in neonates. (1) In the present case, the baby was born prematurely, before such an intervention could have been considered. 
